Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BioTTT001
- Development stage
- Phase 2
- Lead developer
- Beijing Bio-Targeting Therapeutics Technology
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
BioTTT001 is a recombinant oncolytic adenovirus 5 (Ad5) encoding non-secreting interleukin-12 (nsIL-12). Upon administration, it specifically infects and replicates in tumor cells, leading to viral-mediated tumor cell lysis. The released virus particles can then infect neighboring tumor cells, amplifying the antitumor effect. The encoded nsIL-12 acts as an agonist to stimulate immune responses within the tumor microenvironment. BioTTT001 is being developed primarily for the treatment of recurrent or progressive high-grade glioma and other malignant solid tumors. It is currently under clinical investigation in Phase 1/2 trials in China[1][2][3][8].
- Other names
- recombinant human nsIL12 oncolytic adenovirus injection
02
Targets
IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on BioTTT001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioTTT001.